Références : Incidence du cancer au Canada : tendances et projections (1983-2032) - PSPMC: Volume 35, supplément 1, Printemps 2015

Références

1Comité consultatif de la Société canadienne du cancer. Statistiques canadiennes sur le cancer 2013. Toronto (Ont.), Société canadienne du cancer, 2013.
2 National Cancer Registry. Trends in Irish cancer incidence 1994–2002 with predictions to 2020 [Internet]. Cork (IE): National Cancer Registry; 2006 [consultation le 28 octobre 2013].
3Møller B, Fekjær H, Hakulinen T et collab. Prediction of cancer incidence in the Nordic countries up to the year 2020. Eur J Cancer Prev. 2002;Suppl 11:S1-96.
4Mistry M, Parkin DM, Ahmad AS, Sasieni P. Cancer incidence in the United Kingdom: projections to the year 2030. Br J Cancer. 2011;105:1795-803.
5 New Zealand: Ministry of Health. Cancer in New Zealand: trends and projections [Internet]. New Zealand: Ministry of Health; 2002 [consultation le 28 octobre 2013].
6Organisation mondiale de la Santé. Classification internationale des maladies, 9e révision. Volumes 1 et 2. Genève (CH), Organisation mondiale de la Santé, 1977.
7Fritz A, Percy C, Jack A et collab. Classification internationale des maladies pour l'oncologie, 3e éd. Genève (CH), Organisation mondiale de la Santé, 2000.
8National Cancer Institute. SEER incidence site recode [Internet]. Bethesda (MD): National Cancer Institute; 2003 [consultation le 28 octobre 2013].
9Statistique Canada. Compendium des estimations démographiques 2010. Ottawa (Ont.), Ministère de l'Industrie, 2010, tableau 051-0001 de CANSIM, publié le 29 septembre 2010.
10Statistique Canada. Projections démographiques pour le Canada, les provinces et les territoires 2009 à 2036 [Internet]. Ottawa, Ministère de l'Industrie, 2010 [consultation le 28 octobre 2013]. [No 91-520-X au catalogue de Statistique Canada]. [Statistics Canada, Catalogue No. 91-520-X]
11Breslow N, Day N. Statistical methods in cancer research. Volume 2: The design and analysis of cohort studies. Lyon (FR): IARC Scientific Publications no. 82; 1987.
12Hakulinen T, Dyba T. Precision of incidence predictions based on Poisson distributed observations. Stat Med. 1994;13:1513-23.
13Dyba T, Hakulinen T. Comparison of different approaches to incidence prediction based on simple interpolation techniques. Stat Med. 2000;19:1741-52.
14Holford TR. The estimation of age, period and cohort effects for vital rates. Biometrics. 1983;39:311-24.
15Moller B, Fekjaer H, Hakulinen T et collab. Prediction of cancer incidence in the Nordic countries: Empirical comparison of different approaches. Stat Med. 2003;22:2751-66.
16Osmond C. Using age, period and cohort models to estimate future mortality rates. Int J Epidemiol. 1985;14:124-9.
17McCullagh P, Nelder JA. Generalized linear models, 2nd ed. London (UK): Chapman and Hall; 1989.
18Hastie TJ, Tibshirani RJ. Generalized additive models. London (UK): Chapman and Hall; 1990.
19Wood SN. Generalized additive models: an introduction with R. Boca Raton (Fl): Chapman and Hall; 2006.
20Verdecchia A, De Angelis G, Capocaccia R. Estimation and projections of cancer prevalence from cancer registry data. Stat Med. 2002;21:3511-26.
21Carstensen B. Age-period-cohort models for the lexis diagram. Stat Med. 2007;26:3018- 45.
22Bray I. Application of Markov chain Monte Carlo methods to projecting cancer incidence and mortality. J R Stat Soc Ser C, Appl Stat. 2002;51:151-64.
23Robert CP, Casella G. Monte Carlo Statistical Methods. New York: Springer-Verlag; 1999.
24Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27:2758-2765.
25Cancer Registry of Norway. Nordpred software package [software]. Oslo (NO): Institute of Population-Based Research; 2009 [cited 2013 Oct 28].
26Clayton D, Schifflers E. Models for temporal variation in cancer rates. II: Age-period-cohort models. Stat Med. 1987;6:469-81.
27Lee TC, Dean CB, Semenciw R. Short-term cancer mortality projections: a comparative study of prediction methods. Stat Med. 2011;30:3387-402.
28Moller H, Fairley L, Coupland V et collab. The future burden of cancer in England: incidence and numbers of new patients in 2020. Br J Cancer. 2007;96:1484-8.
29Coupland VH, Okello C, Davies EA, Bray F, Møller H. The future burden of cancer in London compared with England. J Public Health (Oxf). 2010;32:83-9.
30Aitken R, Morell S, Barraclough H et collab. Cancer incidence and mortality projections in New South Wales, 2007 to 2011. New South Wales: Cancer Institute; 2008.
31Olsen AH, Parkin DM, Sasieni P. Cancer mortality in the United Kingdom: Projections to the year 2025. Br J Cancer. 2008;99:1549- 54.
32Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing. 2000;10:325-37.
33Ntzoufras I. Bayesian Modeling Using WinBUGS. Hoboken, New Jersey (NY): John Wiley & Sons; 2009.
34Spiegelhalter DJ, Thomas A, Best NG, Lunn D. BUGS Examples Volume 2 [Internet]. Cambridge (UK): The BUGS Project; 1996 [cited 2013 Oct 28].
35Cancer Registry of Norway. Cancer in Norway 2005—Special issue: Predictions of cancer incidence by health region 2010–2020 [Internet]. Oslo (NO): Cancer Registry of Norway; 2012 [cited 2013 Oct 28].
36Comité directeur des statistiques sur le cancer de la Société canadienne du cancer. Statistiques canadiennes sur le cancer 2011. Toronto (Ont.), Société canadienne du cancer, 2011.
37Band PR, Gaudette LA, Hill GB et collab. Développement du registre canadien du cancer : incidence du cancer au Canada et dans les régions canadiennes, 1969 à 1988. Ottawa, Ministre des Approvisionnements et Services, 1993.
38Pelletier G. La survie reliée au cancer : étude des nouveaux cas de cancer déclarés au Québec au cours des années 1984, 1985, et 1986. Collection Données statistiques et Indicateurs. Québec, Gouvernement du Québec, Ministère de la Santé et des Services sociaux, Direction générale de la planification et de l'évaluation, 1993.
39Larsen RJ, Marx ML. An introduction to mathematical statistics and its applications, 3rd ed. Upper Saddle River (NJ): Prentice Hall; 2001.
40Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335-51.
41National Cancer Institute. Joinpoint regression program [Internet software]. Bethesda (MD): National Cancer Institute; 2013 [updated 2013 May 6; cited 2013 Oct 30].
42Institut national du cancer au Canada. Statistiques canadiennes sur le cancer 2000. Toronto (Ont.), Institut national du cancer du Canada, 2000.
43Santé Canada. Enquête de surveillance de l'usage du tabac au Canada (ESUTC) 2011 [Internet]. Ottawa (Ont.), Santé Canada; 2011 [consultation le 4 septembre 2013].
44Weiss W. Cigarette smoking and lung cancer trends. A light at the end of the tunnel? Chest. 1997;111:1414-6.
45Canadian Partnership Against Cancer. Cervical cancer screening in Canada: programs and strategies [Internet]. Toronto (ON): Canadian Partnership Against Cancer; 2013 [updated 2013 Mar; cited 2013 Oct 28].
46Partenariat canadien contre le cancer. Lutte contre le cancer du col de l'utérus au Canada [Internet]. Toronto (Ont.), Partenariat canadien contre le cancer, 2013 [mise à jour le 20 août 2012; consultation le 28 octobre 2013].
47Centre international de recherche sur le cancer. Agents classés par les monographies du CIRC, volumes 1-109, Monographies du CIRC sur l'évaluation des risques de cancérogénicité pour l'homme [Internet]. Lyon (FR) : Centre international de recherche sur le cancer, 2013 [mise à jour le 30 octobre 2013; consultation le 21 décembre 2013].
48Turati F, Garavello W, Tramacere I, et collab. A meta-analysis of alcohol drinking and oral and pharyngeal cancers: results from subgroup analyses. Alcohol Alcohol. 2013;48:107-18.
49Gandini S, Botteri E, Iodice S et collab. Tobacco smoking and cancer: a meta-analysis. Int J Cancer. 2008;122:155-64.
50Bagnardi V, Blangiardo M, La Vecchia C, Corrao G. A meta-analysis of alcohol drinking and cancer risk. Br J Cancer. 2001;85:1700-5.
51Statistique Canada. Tendances de la santé 2013[Internet]. Ottawa (Ont.), Statistique Canada, 2013 [consultation le 28 octobre 2013]. [No 82-213-XWF au catalogue de Statistique Canada].
52Kufe DW, Bast Jr RC, Hait WN, et collab. Cancer medicine, 7th ed. Hamilton (ON): BC Decker Inc.; 2006.
53Haskell CM. Cancer treatment, 5th ed. Philadelphia (PA): WB Saunders Company; 2001.
54Forte T, Niu J, Lockwood GA, Bryant HE. Incidence trends in head and neck cancers and human papillomavirus (HPV)-associated oropharyngeal cancer in Canada, 1992-2009. Cancer Causes Control. 2012;23(8):1343-8.
55Johnson-Obaseki S, McDonald JT, Corsten M, Rourke R. Head and neck cancer in Canada: trends 1992 to 2007. Otolaryngol Head Neck Surg. 2012;147(1):74-8.
56Jemal A, Simard EP, Dorell C et collab. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105(3):175-201.
57Blomberg M, Nielsen A, Munk C, Kjaer SK. Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites. Int J Cancer. 2011;129(3):733-41.
58Shin A, Jung YS, Jung KW, Kim K, Ryu J, Won YJ. Trends of human papilloma virus related head and neck cancers in Korea: National cancer registry data. Laryngoscope. 2013 Nov;123(11):E30-7.
59Comité consultatif national de l'immunisation (CCNI).Mise à jour sur les vaccins contre les virus du papillome humain (VPH). Une déclaration d'un comité consultatif (DCC). CCNI 2012:38 (ACS-1). Ottawa (Ont.), Agence de la santé publique du Canada; [mise à jour le 27 août 2012; consultation le 21 décembre 2013].
60Wilson SE, Harris T, Sethi P, Fediurek J, Macdonald L, Deeks SL. Coverage from Ontario, Canada's school-based HPV vaccine program: the first three years. Vaccine. 2013;31(5):757-62.
61Comité directeur des statistiques sur le cancer de la Société canadienne du cancer. Statistiques canadiennes sur le cancer 2010. Toronto (Ont.), Société canadienne du cancer, 2010.
62Lagergren J. Etiology and risk factors for oesophageal adenocarcinoma: possibilities for chemoprophylaxis? Best Pract Res Clin Gastroenterol. 2006;20:803-12.
63Blot WJ, McLaughlin JK, Fraumeni JF Jr. Esophageal cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention, 3rd ed. New York (NY): Oxford University Press; 2006. p. 697-706.
64Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol. 2012; 23:3155-62.
65Freedman ND, Abnet CC, Leitzmann MF, et collab. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol. 2007;165:1424- 33.
66Lee YC,MarronM, Benhamou S, et collab. Active and involuntary tobacco smoking and upper aerodigestive tract cancer risks in a multicenter case-control study. Cancer Epidemiol Biomarkers Prev. 2009;18:3353-61.
67Engel LS, Chow WH, Vaughan TL, et collab. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003;95:1404-13.
68Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013;63:232-48.
69Fedorak RN, van Zanten SV, Bridges R. Canadian Digestive Health Foundation Public Impact Series: gastroesophageal reflux disease in Canada: incidence, prevalence, and direct and indirect economic impact. Can J Gastroenterol. 2010;24:431-4.
70Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569-78.
71Steffen A, Schulze MB, Pischon T, et collab. Anthropometry and esophageal cancer risk in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2009;18:2079-89.
72Tjepkema, M. L'obésité chez les adultes au Canada : Poids et grandeur mesurés. Dans: Nutrition : Résultats de l'Enquête sur la santé dans les collectivités canadiennes, no 1. [No 82-620-MWF au catalogue de Statistique Canada]. Ottawa (Ont.), Statistique Canada, 2006.
73Agence de la santé publique du Canada. Obésité au Canada[Internet]. Ottawa (Ont.), Agence de la santé publique au Canada, 2011 [mise à jour le 23 juin 2011; consultation le 28 octobre 2013].
74El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2007;5:17-26.
75Statistique Canada. Population selon certaines origines ethniques, par province et territoire (Recensement de 2006).[Internet]. Ottawa (Ont.), Statistique Canada [mise à jour le 28 juillet 2009; consultation le 28 juillet 2009].
76Organisation mondiale de la Santé. Hépatite B. Aide-mémoire no 204[Internet]. Genève (CH), Organisation mondiale de la Santé, 2013 [mise à jour en juillet 2013; consultation le 28 octobre 2013].
77Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212-9.
78Burak KW, Coffin CS, Myers RP. Hepatitis B awareness and education: a failing grade. Can J Gastroenterol. 2011;25:125-6.
79Nagini S. Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol. 2012;4(7):156-69.
80D'Elia L, Rossi G, Ippolito R, Cappuccio FP, Strazzullo P. Habitual salt intake and risk of gastric cancer: a meta-analysis of prospective studies. Clin Nutr. 2012;31(4):489-98.
81Statistique Canada. Statistiques sur les aliments 2009. Ottawa (Ont.), Statistique Canada, 2009 [consultation le 28 octobre 2013]. [N o 21-020-XWF au catalogue de Statistique Canada].
82Howson CP, Hiyama T, Wynder EL. The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiol Rev. 1986;8:1-27.
83International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 61. Lyon (FR): IARC Press; 1994.
84Agence de la santé publique du Canada. Cancer colorectal[Internet]. Ottawa (Ont.), Agence de la santé publique du Canada, 2013 [mise à jour le 22 avril 2013; consultation le 28 octobre 2013].
85Cancer Research UK. Bowel cancer risk factors [Internet]. London (UK): Cancer Research UK; 2012 [mise à jour le 31 janvier 2012; consultation le 28 octobre 2013].
86Boyle P, Levin B, editors. World Cancer report 2008 [Internet]. Lyon (FR): International Agency for Research on Cancer; 2008 [consultation le 28 octobre 2013].
87Aune D, Lau R, Chan DS, et collab. Nonlinear reduction in risk for colorectal cancer by fruit and vegetable intake based on meta-analysis of prospective studies. Gastroenterology. 2011;141:106-18.
88Labonte R, Muhajarine N, Winquist B, Quail J. Healthy populations: a report of the Canadian index of wellbeing (CIW) [Internet]. Waterloo (ON): Waterloo University; September 2010 [consultation le 28 octobre 2013].
89Lin KJ, Cheug WY, Lai JY, Giovannucci EL. The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer. Int J Cancer. 2012;130:419-30.
90Garriguet D. Les habitudes alimentaires des Canadiens. Rapports sur la santé, 2007;18:17- 33.
91Nesbitt A, Majowicz S, Finley R. Food consumption patterns in the Waterloo Region, Ontario, Canada: a cross-sectional telephone survey. BMC Public Health. 2008;8:370.
92Edwards BK, Ward E, Kohler BA et collab. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544-573.
93Edwards BK, Noone AM, Mariotto AB et collab. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120;1290-314.
94Partenariat canadien contre le cancer. Dépistage du cancer colorectal - 2010[Internet]. Toronto (Ont.), Partenariat canadien contre le cancer, 2010 [consultation le 21 décembre 2013].
95Kadiyala S, Strumpf EC. Are United States and Canadian cancer screening rates consistent with guideline information regarding the age of screening initiation? Int J Qual Health Care. 2011;23:611-20.
96El-Seraq HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118-27.
97Yang JD, Kim B, Sanderson SO et collab. Hepatocellular carcinoma in Olmsted County, Minnesota, 1976-2008. Mayo Clin Proc. 2012;87:9-16.
98Dyer Z, Peltekian K, van Zanten SV. Review article: the changing epidemiology of hepatocellular carcinoma in Canada. Aliment Pharmacol Ther. 2005;22:17-22.
99Agence de la santé publique du Canada. L'hépatite C au Canada : Rapport de surveillance de 2005-2010[Internet]. Ottawa (Ont.), Agence de la santé publique du Canada, 2012 [consultation le 21 décembre 2013].
100Bosch FX, Rives J, Diaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastrenterology. 2004;127:S7-16.
101Zou S, Tepper M, El Saadany S. Prediction of hepatitis C burden in Canada. Can J Gastroenterol. 2000;14:575-80.
102Agence de la santé publique du Canada. Stratégie nationale d'immunisation : Rapport final 2003.Ottawa (Ont.), Agence de la santé publique du Canada, 2004 [mise à jour le 16 juin 2004; consultation le 28 octobre 2013].
103Agence de la santé publique du Canada. Maladies pouvant être prévenues par la vaccination[Internet]. Ottawa (Ont.), Agence de la santé publique du Canada, 2012 [mise à jour le 20 juillet 2012; consultation le 28 octobre 2013].
104McDermott S, DesMeules M, Lewis R et collab. Cancer incidence among Canadian immigrants, 1980-1998: results from a national cohort study. J Immigr Minor Health. 2011;13:15-26.
105Statistique Canada. Population immigrante selon le lieu de naissance, par province et territoire (Recensement de 2006)[Internet]. Ottawa (Ont.), Statistique Canada, 2007 [mise à jour le 11 décembre 2007; consultation le 28 octobre 2013].
106Statistique Canada. Certaines tendances relatives aux données pour Canada, recensements de 1996, 2001 et 2006[Internet]. Ottawa (Ont.), Statistique Canada, 2010 [mise à jour le 6 février 2010; consultation le 28 octobre 2013].
107Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010;42 Suppl 3:S206-14.
108Eheman C, Henley SJ, Ballard-Barbash R et collab. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118:2338-66.
109Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47 Suppl:S2-6.
110Shields M, Tremblay MS, Laviolette M, Craig CL, Janssen I, Connor Gorber S. Condition physique des adultes au Canada : Résultats de l'Enquête canadienne sur les mesures de la santé, 2007-2009. Rapports sur la santé. 2010;21:21-35.
111Devita VT Jr, Hellman S, Rosenberg SA. Cancer: principles & practice of oncology, 7th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2005.
112Villeneuve PJ, Johnson KC, Mao Y, Hanley AJ. Environmental tobacco smoke and the risk of pancreatic cancer: findings from a Canadian population-based case-control study. Can J Public Health. 2004;95:32-7.
113Gallicchio L, Kouzis A, Genkinger J et collab. Active cigarette smoking, household passive smoke exposure, and the risk of developing pancreatic cancer. Prev Med. 2006;42:200-5.
114Weiss W, Benarde MA. The temporal relation between cigarette smoking and pancreatic cancer. Am J Public Health. 1983;73:1403-4.
115Silverman DT, Schiffman M, Everhart J et collab. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer. 1999;80:1830-7.
116Ghadirian P, Lynch HT, Krewski D. Epidemiology of pancreatic cancer: an overview. Cancer Detect Prev. 2003;27:87- 93.
117World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project: keeping the science current. Pancreatic cancer 2012 report: food, nutrition, physical activity, and the prevention of pancreatic cancer [Internet]. World Cancer Research Fund; 2012 [consultation le 21 décembre 2013].
118Bao Y, Michaud DS, Spiegelman D. Folate intake and risk of pancreatic cancer: pooled analysis of prospective cohort studies. J Natl Cancer Inst. 2011;103:1840-50.
119Aune D, Greenwood DC, Chan DS et collab. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol. 2012;23:843-52.
120O'Rorke M, Cantwell MM, Cardwell CR, Mulholland HG, Murray LJ. Can physical activity modulate pancreatic cancer risk? a systematic review and meta-analysis. Int J Cancer. 2010;126:2957-68.
121Bao Y, Michaud DS. Physical activity and pancreatic cancer risk: a systematic review. Cancer Epidemiol Biomarkers Prev. 2008;17:2671-82.
122Ben Q, Xu M, Ning X et collab. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer. 2011;47:1928-37.
123Elena JW, Steplowski E, Yu K et collab. Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Cancer Causes Control. 2013;24:13-25.
124Cancer Research UK. Pancreatic cancer incidence statistics [Internet]. London (UK): Cancer Research UK; 2013 [mise à jour le 18 octobre 2013; consultation le 28 octobre 2013].
125Berrino F, Crosignani P. [Epidemiology of malignant tumors of the larynx and lung]. Ann Ist Super Sanita. 1992;28:107-20.
126Burch JD, Howe GR, Miller AB, Semenciw R. Tobacco, alcohol, asbestos, and nickel in the etiology of cancer of the larynx: a casecontrol study. J Natl Cancer Inst. 1981;67: 1219-24.
127Santé Canada. Enquête de surveillance canadienne de la consommation d'alcool et de drogues : Sommaire des résultats pour 2011. Ottawa (Ont.), Santé Canada, 2012 [mise à jour le 3 juillet 2012; consultation le 28 octobre 2013].
128Surgeon General. Reducing the health consequences of smoking: 25 years of progress. Washington (DC): U.S. Department of Health and Human Services, Centers for Disease Control; 1989.
129Shopland DR. Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. Environ Health Perspect. 1995;103:131-42.
130Brisson J, Major D, Pelletier E. É valuation de l'exhaustivité du fichier des tumeurs du Québec. Québec (QC): Institut national de la santé publique du Québec; 2003.
131Sneyd M, Cox B. The control of melanoma in New Zealand. N Z Med J. 2006;119:U2169.
132Gandini S, Sera F, Cattaruzza MS et collab. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41:45-60.
133Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer. 1997;73:198-203.
134Miller AJ, Mihm MC, Jr. Melanoma. N Engl J Med. 2006;355:51-65.
135Naldi L, Randi G, Di Landro A, La Vecchia C. Red hHairs, number of nevi, and risk of cutaneous malignant melonoma: results from a case-control study in Italy. Arch Dermatol. 2006;142:935-6.
136Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for melanoma: a meta-analysis of pigmentary characteristics and freckling. Int J Cancer. 2010;127:2430-45.
137Williams PF, Olsen CM, Hayward NK, Whiteman DC. Melanocortin 1 receptor and risk of cutaneous melanoma: a metaanalysis and estimates of population burden. Int J Cancer. 2011;129:1730-40.
138Olsen CM, Carroll HJ, Whiteman DC. Familial melanoma: a meta-analysis and estimates of attributable fraction. Cancer Epidemiol Biomarkers Prev. 2010;19:65-73.
139Gandini S, Sera F, Cattaruzza MS et collab. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005;41:2040-59.
140Law MH, Macgregor S, Hayward NK. Melanoma genetics: recent findings take us beyond well-traveled pathways. J Invest Dermatol. 2012;132:1763-74.
141Erdmann F, Lortet-Tieulent J, Schüz J et collab. International trends in the incidence of malignant melanoma 1953-2008—are recent generations at higher or lower risk? Int J Cancer. 2013;132:385-400.
142Shields M, Wilkins K. Le point sur la mammographie au Canada. Rapports sur la santé, 2009;20:1-15.
143Groupe d'étude canadien sur les soins de santé préventifs. Dépistage du cancer du sein - Résumé des recommandations pour les cliniciens et les responsables des politiques [Internet]. Edmonton (AB), Groupe d'étude canadien sur les soins de santé préventifs, 2014 [consultation le 28 mars 2014].
144Association canadienne des radiologistes. Lignes directrices de pratique et normes techniques de la CAR en matière d'imagerie du sein et d'intervention. Ottawa (Ont.), Association canadienne des radiologistes [mise à jour le 29 septembre 2012; consultation le 18 mars 2014].
145Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ. 2004;328:921-4.
146Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348: g366.
147Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol. 2001;2:133- 40.
148Ford D, Nault F. Changements des tendances de la fécondité, 1974-1994. Rapports sur la santé. 1996;8:43-51.
149Statistique Canada. Naissances et indice synthétique de fécondité, par province et territoire (Fécondité)[Internet]. Ottawa, Statistique Canada [mise à jour le 19 mars 2013; consultation le 6 septembre 2013].
150Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288:872-81.
151Cancer Research UK. Breast cancer risk factors [Internet]. London (UK): Cancer Research UK [mise à jour le 17 décembre 2013; consultation le 19 décembre 2013]. Available from:
152Rossouw JE, Anderson GL, Prentice RL et collab. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-33.
153De P, Neutel CI, Olivotto I, Morrison H. Breast cancer incidence and hormone replacement therapy in Canada. J Natl Cancer Inst. 2010;102(19):1489-95.
154Boyd NF, Martin LJ, Sun L et collab. Body size, mammographic density, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:2086-92.
155Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res. 2011;13:223.
156Boyd N, Martin L, Stone J, Little L, Minkin S, Yaffe M. A longitudinal study of the effects of menopause on mammographic features. Cancer Epidemiol Biomarkers Prev. 2002;11(10 Pt 1):1048-53.
157Huo CW, Chew GL, Britt KL et collab. Mammographic density-a review on the current understanding of its association with breast cancer. Breast Cancer Res Treat. 2014;144:479-502.
158Bertrand KA, Tamimi RM, Scott CG et collab. Mammographic density and risk of breast cancer by age and tumor characteristics. Breast Cancer Res. 2013;15:R104.
159Parkin DM, Boyd L, Walker LC. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Summary and conclusions. Br J Cancer. 2011;105:S77-81.
160Monninkhof EM, Elias SG, Vlems FA. Physical activity and breast cancer: a systematic review. Epidemiology. 2007;18:137- 157.
161Kobayashi LC, Janssen I, Richardson H, Lai AS, Spinelli JJ, Aronson KJ. A case-control study of lifetime light intensity physical activity and breast cancer risk. Cancer Causes Control. 2014;25(1):133-40.
162Baan R, Straif K, Grosse Y et collab. WHO International Agency for Research on Cancer Monograph Working Group. Carcinogenicity of alcoholic beverages. Lancet Oncol. 2007; 8:292-3.
163Cogliano VJ, Baan R, Straif K et collab. Preventable exposures associated with human cancers. J Natl Cancer Inst. 2011;103:1827-39.
164Reynolds P. Smoking and breast cancer. J Mammary Gland Biol Neoplasia. 2013;18:15- 23.
165Johnson KC, Miller AB, Collishaw NE et collab. Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk (2009). Tob Control. 2011;20:e2.
166Walboomers JM, Jacobs MV, Manos MM et collab. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-9.
167Ferenczy A, Franco E. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol. 2002;3:11-6.
168Deneris A, Bond S. Clinical update: human papillomavirus vaccine. J Midwifery Womens Health. 2006;51:515-8.
169Moore RA, Ogilvie G, Fornika D et collab. Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women—implications for vaccination. Cancer Causes Control. 2009;20:1387-96.
170Palefsky JM, Holly EA. Chapter 6: Immunosuppression and co-infection with HIV. J Natl Cancer Inst Monogr. 2003;31:41- 46.
171Parkin DM. Tobacco-attributable cancer burden in the UK in 2010. Br J Cancer. 2011;105:S6-13.
172Colucci R, Hryniuk W, Savage C. HPV vaccination programs in Canada: are we hitting the mark? In: Cancer Advocacy Coalition of Canada. Report card on cancer in Canada, 2008 [Internet]. Cancer Advocacy Coalition of Canada; 2008 [consultation le 6 septembre 2013].
173Agence de la santé publique du Canada. La prévention du virus du papillome humain (VPH) et le vaccin contre le VPH : Questions et réponses[Internet]. Ottawa (Ont.), Agence de la santé publique du Canada, 2011 [mise à jour le 31 mars 2011; consultation le 6 septembre 2013].
174Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol. 2005;6:552-3.
175Cust AE, Armstrong BK, Friedenreich CM, Slimani N, Bauman A. Physical activity and endometrial cancer risk: a review of the current evidence, biologic mechanisms and the quality of physical activity assessment methods. Cancer Causes Control. 2007;18: 243-58.
176Zhang Y, Liu H, Yang S, Zhang J, Qian L, Chen X. Overweight, obesity and endometrial cancer risk: results from a systematic review andmeta-analysis. Int J BiolMarkers. 2014;29(1):e21-9.
177Arem H, Irwin ML, Zhou Y, Lu L, Risch H, Yu H. Physical activity and endometrial cancer in a population-based case-control study. Cancer Causes Control. 2011;22:219-26.
178Voskuil DW, Monninkhof EM, Elias SG, Vlems FA, van Leeuwen FE, Task Force Physical Activity and Cancer. Physical activity and endometrial cancer risk, a systematic reviewof current evidence. Cancer Epidemiol Biomarkers Prev. 2007;16:639-48.
179Bray F, dos Santos Silva I, Moller H, Weiderpasse E. Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev. 2005;14:1132-42.
180Evans T, Sany O, Pearmain P, Ganesan R, Blann A, Sundar S. Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006. Br J Cancer. 2011;104:1505-10.
181Fisher WA, Black A. Contraception in Canada: a review of method choices, characteristics, adherence and approaches to counselling. CMAJ. 2007;176:953-61.
182Dossus L, Allen N, Kaaks R et collab. Reproductive risk factors and endometrial cancer: the European prospective investigation into cancer and nutrition. Int J Cancer. 2010;127:442-51.
183Tortolero-Luna G, Mitchell MF. The epidemiology of ovarian cancer. J Cell Biochem Suppl. 1995;23:200-7.
184Kelsey JL, Whittemore AS. Epidemiology and primary prevention of cancers of the breast, endometrium, and ovary: a brief overview. Ann Epidemiol. 1994;4:89-95.
185Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol. 2012;55:3-23.
186Goldman MB, Hatch M. Women and Health. Waltham (MA): Academic Press; 1999.
187Salehi F, Dunfield L, Phillips KP, Krewski D, Vanderhyden BC. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Environ Health B Crit Rev. 2008;11:301-21.
188Pearce CL, Chung K, Pike MC, Wu AH. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer. 2009;115:531-9.
189Beral V, Million Women Study Collaborators, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007;369:1703-10.
190Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2007;96:11-5.
191Gayther SA, Pharoah PD. The inherited genetics of ovarian and endometrial cancer. Curr Opin Genet Dev. 2010;20:231-8.
192Granstrom C, Sundquist J, Hemminki K. Population attributable fractions for ovarian cancer in Swedish women by morphological type. Br J Cancer. 2008;98:199-205.
193Negri E, Pelucchi C, Franceschi S et collab. Family history of cancer and risk of ovarian cancer. Eur J Cancer. 2003;39:505-10.
194Secretan B, Straif K, Baan R et collab. A review of human carcinogens-Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol. 2009;10:1033-4.
195Canadian Task Force on the Periodic Health Examination. Periodic health examination, 1991 update 3. Secondary prevention of prostate cancer. CMAJ. 1991;145:413-28.
196Levy IG, Gibbons L, Collins JP, Perkins DG, Mao Y. Prostate cancer trends in Canada: rising incidence or increased detection? CMAJ. 1993;149:617-24.
197Comité directeur de la Société canadienne du cancer. Statistiques canadiennes sur le cancer 2006. Toronto (Ont.), Société canadienne du cancer, 2006.
198Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993;119:914-23.
199Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA. 2014;311:1143-9.
200Evans HS,Møller H. Recent trends in prostate cancer incidence and mortality in southeast England. Eur Urol. 2003;43:337-41.
201Brawley OW. Trends in prostate cancer in the United States. J Natl Cancer Inst Monogr. 2012;2012:152-6.
202Kicinski M, Vangronsveld J, Nawrot TS. An epidemiological reappraisal of the familial aggregation of prostate cancer: a metaanalysis. PLoS ONE. 2011;6:e27130.
203Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer. 2003;107:797-803.
204Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int. 2003;91:794.
205Hemminki K, Czene K. Age specific and attributable risks of familial prostate carcinoma from the family-cancer database. Cancer. 2002;95:1346-53.
206Ferlay J, Shin HR, Bray F, Forman D,Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon (FR): International Agency for Research on Cancer; 2010.
207Parkin DM, Ferlay J, Hamdi-Cherif M et collab. Cancer in Africa: epidemiology and prevention. 1st ed. Lyon (FR): IARC Scientific Publications no.153; 2003.
208Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012; 30:195-200.
209Leitzmann MF, Rohrmann S. Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin Epidemiol. 2012;4:1-11.
210Chen L, Stacewicz-Sapuntzakis M, Duncan C et collab. Oxidative DNA damage in prostate cancer patients consuming tomato saucebased entrees as a whole-food intervention. J Natl Cancer Inst. 2001;93:1872-1879.
211Yan L, Spitznagel EL. Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. AmJ Clin Nutr. 2009;89:1155- 63.
212Gao X, LaValley MP, Tucker KL. Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis. J Natl Cancer Inst. 2005;97:1768-77.
213Gann PH. Risk factors for prostate cancer. Rev Urol. 2002;4 Suppl 5:S3-10.
214McGlynn KA, Devesa SS, Sigurdson AJ, Brown LM, Tsao L, Tarone RE. Trends in the incidence of testicular germ cell tumors in the United States. Cancer. 2003;97:63-70.
215Bray F, Richiardi L, Ekbom A, Pukkala E, Cuninkova M, Møller H. Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer. 2006;118:3099-111.
216Power DA, Brown RS, Brock CS, Payne HA, Majeed A, Babb P. Trends in testicular carcinoma in England and Wales, 1971-99. BJU Int. 2001;87:361-5.
217Stone JM, Cruickshank DG, Sandeman TF, Matthews JP. Trebling of the incidence of testicular cancer in Victoria, Australia (1950-1985). Cancer. 1991;68:211-9.
218Møller H, Fairley L, Coupland V et collab. The future burden of cancer in England: incidence and numbers of new patients in 2020. Br J Cancer. 2007;96(9):1484-8.
219Pettersson A, Richiardi L, Nordenskjold A et collab. Age at surgery for undescended testis and risk of testicular cancer. N Engl J Med. 2007;356:1835-41.
220Zhang Y, Graubard BI, Klebanoff MA et collab. Maternal hormone levels among populations at high and low risk of testicular germ cell cancer. Br J Cancer. 2005;92:1787-93.
221Sharpe RM, Skakkebaek NE. Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? Lancet. 1993;341:1392-5.
222Skakkebaek NE, Rajpert-De Meyts E, Jørgensen N et collab. Germ cell cancer and disorders of spermatogenesis: an environmental connection? APMIS. 1998;106:3-12.
223Hemminki K, Chen B. Familial risks in testicular cancer as aetiological clues. Int J Androl. 2006;29:205-10.
224Chow WH, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J. 2008;14:288-301.
225Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281:1628-31.
226Liu S, Semenciw R, Morrison H, Schanzer D, Mao Y. Kidney cancer in Canada: the rapidly increasing incidence of adenocarcinoma in adults and seniors. Can J Public Health. 1997;88:99-104.
227Mathew A, Devesa SS, Fraumeni JF Jr, Chow WH. Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev. 2002;11:171-8.
228Levi F, Ferlay J, Galeone C et collab. The changing patterns of kidney cancer incidence and mortality in Europe. BJU Int. 2008;101:949-58.
229Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7:245-57.
230Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012;62:118-28.
231Patard JJ. Incidental renal tumours. Curr Opin Uro. 2009;19:454-8.
232Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: An analysis of surveillance, epidemiology, and end results program data. J Urol. 2002;167: 57-60.
233Moore LE, Wilson RT, Campleman SL. Lifestyle factors, exposures, genetic susceptibility, and renal cell cancer risk: a review. Cancer Invest. 2005;23:240-55.
234Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol. 2006;176:2353-8.
235Hu J, Ugnat AM. Active and passive smoking and risk of renal cell carcinoma in Canada. Eur J Cancer. 2005;41:770-8.
236Chow WH, Grindley G, Fraumeni JF Jr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343:1305-11.
237Bao C, Yang X, Xu W et collab. Diabetes mellitus and incidence and mortality of kidney cancer: A meta-analysis. J Diabetes Complications. 2013;Feb 20.
238Bonsib SM. Renal cystic diseases and renal neoplasms: a mini-review. Clin J Am Soc Nephrol. 2009;4:1998-2007.
239Curado FJA, Hernandez PC, Castro RP et collab. New epidemiologic patterns and risk factors in renal cancer. Actas Urol Esp. 2009;33:459-67.
240.Karami S, Lan Q, Rothman N et collab. Occupational trichloroethylene exposure and kidney cancer risk: a meta-analysis. Occup Environ Med. 2012;69:858-67.
241Lynch CF, Platz CE, Jones MP, Gazzaniga JM. Cancer registry problems in classifying invasive bladder cancer. J Natl Cancer Inst. 1991;83:429-33.
242Hankey BF, Edwards BK, Ries LA, Percy CL, Shambaugh E. Problems in cancer surveillance: Delineating in situ and invasive bladder cancer. J Natl Cancer Inst. 1991;83:384-5.
243Schned AR, Andrew AS, Marsit CJ, Zens MS, Kelsey KT, Karagas MR. Survival following the diagnosis of noninvasive bladder cancer: WHO/International Society of Urological Pathology versus WHO Classification systems. J Urol. 2007;178:1200.
244Brennan P, Bogillot O, Greiser E et collab. The contribution of cigarette smoking to bladder cancer in women (pooled European data). Cancer Causes Control. 2001;12:411-7.
245Zeegers MP, Tan FE, Dorant E, van den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiological studies. Cancer. 2000;89:630-9.
246Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 2002;10:311-22.
247Olfert SM, Felknor SA, Delclos GL. An updated review of the literature: risk factors for bladder cancer with focus on occupational exposures. SouthMed J. 2006;99:1256-63.
248Letašiová S, Medvéová A, Šovèíková A. Bladder cancer, a review of the environmental risk factors. Environ Health. 2012;11 Suppl 1:S11.
249Kirkali Z, Chan T, Manoharan M et collab. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66:4-34.
250Siemiatycki J, Dewar R, Nadon L, Gérin M. Occupational risk factors for bladder cancer: results froma case-control study inMontreal, Quebec, Canada. Am J Epidemiol. 1994;140: 1061-80.
251Gaertner RR, Trpeski L, Johnson KC. A casecontrol study of occupational risk factors for bladder cancer in Canada. Cancer Causes Control. 2004;15:1007-19.
252Villanueva CM, Fernàndez F, Malats N, Grimalt JO, Kogevinas M. Meta-analysis of studies on individual consumption of chlorinated drinking water and bladder cancer. J Epidemiol Community Health. 2003;57:166-73.
253Villanueva CM, Cantor KP, King WD et collab. Total and specific fluid consumption as determinants of bladder cancer risk. Int J Cancer. 2006;118:2040-7.
254Comité directeur de la Société canadienne du cancer. Statistiques canadiennes sur le cancer 2009. Toronto, Société canadienne du cancer, 2009.
255Preston-Martin S, Munir R, Chakrabarti I. Nervous system. In: Cancer epidemiology and prevention, 3rd ed. Schottenfeld D, Fraumeni JF, editors. New York (NY): Oxford University Press; 2006. p. 1173-95.
256Hemminki K, Tretli S, Olsen JH et collab. Familial risks in nervous system tumours: joint Nordic study. Br J Cancer. 2010;102: 1786-90.
257Kilfoy BA, Zheng T, Holford TR et collab. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control. 2009;20:525-31.
258Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973- 2002. JAMA. 2006;295:2164-7.
259Enewold L, Zhu K, Ron E et collab. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev. 2009;18:784-91.
260Kent WD, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ. 2007;177:1357-61.
261Action Cancer Ontario. L'incidence du cancer de la thyroïde s'accroît en Ontario[Internet]. Toronto (Ont.), Action Cancer Ontario, 2010 [mise à jour le 2mars 2010; consultation le 30 octobre 2013].
262Ron E, Schneider AB. Thyroid Cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention, 3rd ed. New York (NY): Oxford University Press; 2006. p. 975-94.
263Haq M, Harmer C. Thyroid cancer: an overview. Nucl Med Commun. 2004;25:861-7.
264Zabel EW, Alexander BH, Mongin SJ et collab. Thyroid cancer and employment as a radiologic technologist. Int J Cancer. 2006;119:1940-5.
265Ron E, Lubin JH, Shore RE et collab. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res. 1995;141:259-77.
266Peterson E, De P, Nuttall R. BMI, diet and female reproductive factors as risks for thyroid cancer: a systematic review. PLoS ONE. 2012;7:e29177.
267Tsang RW, Hodgson DC, Crump M. Hodgkin's lymphoma. Curr Probl Cancer. 2006;30:107-58.
268Andersson J. Epstein-Barr virus and Hodgkin's lymphoma. Herpes. 2006;13:12-6.
269International Agency for Research on Cancer. Epstein-barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8. IARC monographs on the evaluation of carcinogenic risks to humans, Vol. 70. Lyon (FR), International Agency for Research on Cancer; 1997.
270Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a metaanalysis. Lancet. 2007;370:59-67.
271Goldin LR, Pfeiffer RM, Gridley G et collab. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer. 2004;100:1902-8.
272Sergentanis TN, Kanavidis P, Michelakos T, Petridou ET. Cigarette smoking and risk of lymphoma in adults: a comprehensive metaanalysis on Hodgkin and non-Hodgkin disease. Eur J Cancer Prev. 2013;22:131-50.
273Kamper-Jørgensen M, Rostgaard K, Glaser SL et collab. Cigarette smoking and risk of Hodgkin lymphoma and its subtypes: a pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph). Ann Oncol. 2013;24:2245-55.
274Chang ET, Zheng T,Weir EG et collab. Childhood social environment and Hodgkin's lymphoma: new findings from a populationbased case-control study. Cancer Epidemiol Biomarkers Prev. 2004;13:1361-70.
275Cancer Care Ontario. Cancer Fact: Hodgkin lymphoma incidence highest in young adults and elderly. Cancer Care Ontario; 2006 mise à jour le 21 octobre 2009; consultation le 6 septembre 2013].
276Wang SS, Slager SL, Brennan P et collab. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;109:3479-99.
277Crump C, Sundquist K, Sieh W, Winkleby MA, Sundquist J. Perinatal and family risk factors for non-Hodgkin lymphoma in early life: a Swedish National Cohort Study. J Natl Cancer Inst. 2012;104:923-30.
278Grulich AE, Vajdic CM, Cozen W. Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2007;16:405-8.
279Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci. 2004;95:745-52.
280Dal ML, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2006;15:2078-85.
281Anderson LA, Engels EA. Hepatitis C virus infection and non-Hodgkin lymphoma: interesting association or causal relationship? Int J Cancer. 2008;122:10-2.
282Clarke CA, Glaser SL, Dorfman RF, Bracci PM, EberleE, HollyEA. Expert reviewof non- Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications. Cancer Epidemiol Biomarkers Prev. 2004;13(1):138-43.
283Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92:1240-51.
284Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc. 2010;85:225-30.
285Renshaw C, Ketley N, Møller H, Davies EA. Trends in the incidence and survival of multiple myeloma in South East England 1985-2004. BMC Cancer. 2010;10:74.
286Levi F, Te VC, Randimbison L, La Vecchia C. Incidence of multiple myeloma in Olmsted County, Minnesota. Cancer. 2005;104:442.
287Alexander DD, Mink PJ, Adami HO et collab. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer. 2007;120 Suppl 12:40-61.
288Kristinsson SY, Goldin LR, Björkholm M, Koshiol J, Turesson I, Landgren O. Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica. 2009;94:1581-9.
289Kyle RA, Therneau TM, Rajkumar SV et collab. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-9.
290Larsson SC, Wolk A. Body mass index and risk of multiple myeloma: A meta-analysis. Int J Cancer. 2007;121:2512-6.
291Wallin A, Larson SC. Body mass index and risk of multiple myeloma: a meta-analysis of prospective studies. Eur J Cancer. 2011;47:1606-15.
292Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009;52:611- 22.
293National Cancer Institute. SEER Stat Fact Sheets: Leukemia [Internet]. Bethesda (MD): National Cancer Institute; 2013 [mise à jour le 1er avril 2013; consultation le 19 décembre 2013].
294Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006;107:2099-107.
295International Agency for Research on Cancer. Classification of tumours. Pathology and genetics. Tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
296Kasim K, Levallois P, Abdous B, Auger P, Johnson KC, Canadian Cancer Registries Epidemiology Research Group. Environmental tobacco smoke and risk of adult leukemia. Epidemiology. 2005;16:672-80.
297Gessain A, Cassar O. Epidemiological Aspects and World Distribution of HTLV-1 Infection. Front Microbiol. 2012;3:388.
298International Agency for Research on Cancer. Human immunodeficiency viruses and human T-cell lymphotropic viruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 67. Lyon (FR): IARC Press; 1996.
299Altieri A, Castro F, Bermejo JL, Hemminki K. Number of siblings and the risk of lymphoma, leukemia, and myeloma by histopathology. Cancer Epidemiol Biomarkers Prev. 2006;15:1281-6.
300Slager SL, Caporaso NE, de Sanjose S, Goldin LR. Genetic susceptibility to chronic lymphocytic leukemia. Semin Hematol. 2013;50:296-302.
301Goldin LR, Caporaso NE. Family studies in chronic lymphocytic leukaemia and other lymphoproliferative tumours. Br J Haematol. 2007;139:774-9.
302Crowther-Swanepoel D, Houlston RS. Genetic variation and risk of chronic lymphocytic leukaemia. Semin Cancer Biol. 2010;20:363-9.
303Ito T. Stem cell maintenance and disease progression in chronic myeloid leukemia. Int J Hematol. 2013;98:641-7.
304Liu-Dumlao T, Kantarjian H, Thomas DA, O'Brien S, Ravandi F. Philadelphia-positive acute lymphoblastic leukemia: current treatment options. Curr Oncol Rep. 2012;14:387-94.
305Hoffbrand AV, Moss PAH, Pettit JE. Essential haematology, 5th ed. Oxford: Blackwell Publishing Ltd.; 2006.
306Taylor GM, Birch JM. The hereditary basis of human leukemia. In: Henderson ES, Lister TA, Greaves MJ, editors Leukemia, 6th ed. Philadelphia: WB Saunders; 1996. p. 210-45.
307Lichtman MA. Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist. 2010;15: 1083-101.
308Larsson SC, Wolk A. Overweight and obesity and incidence of leukemia: a metaanalysis of cohort studies. Int J Cancer. 2008;122:1418-21.
309Pan SY, Johnson KC, Ugnat AM, Wen SW, Mao Y. Association of obesity and cancer risk in Canada. Am J Epidemiol. 2004;159: 259-68.
310Kasim K, Johnson KC, Levallois P, Abdous B, Auger P, Canadian Cancer Registries Epidemiology Research Group. Recreational physical activity and the risk of adult leukemia in Canada. Cancer Causes Control. 2009;20:1377-86.
311Marrett LD, Ellison LF, Dryer D. Canadian cancer statistics at a glance: mesothelioma. CMAJ. 2008;178:677-8.
312American Cancer Society. Global Cancer Facts and Figures, 2nd Edition. Atlanta (GA): America Cancer Society; 2011 [consultation le 30 octobre 2013].
313International Agency for Research on Cancer. International Rules for Multiple Primary Cancers (ICD-O Third Edition) [Internet]. Lyon (FR): International Agency for Research on Cancer; 2004 [consultation le 30 octobre 2013].
314Quon H, Loblaw A, Nam R. Dramatic increase in prostate cancer cases by 2021. BJU Int. 2011;108:1734-8.
Signaler un problème ou une erreur sur cette page
Veuillez sélectionner toutes les cases qui s'appliquent :

Merci de votre aide!

Vous ne recevrez pas de réponse. Pour toute question, contactez-nous.

Date de modification :